Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono
10.1016/j.yrtph.2020.104665 [DOI] [PubMed] [Google Scholar] Zemba Cilic A., Zemba M., Cilic M., Balenovic I., Strbe S., Ilic S
Thus, the BPC 157's extension to inflammatory bowel disease (or from inflammatory bowel disease) seems to be well backed presented with favorable both animal data in various models of intestinal damages, and clinical data in inflammatory bowel patients (5-7, 9)
Related Internal Research Resources Research peptide category Testing services and analytical documentation US Chem Labs research FAQ US Chem Labs peptide catalogue External Authority References PubMed: peptide HPLC, mass spectrometry, and stability research NCBI: research peptide analytical documentation PubChem chemical database BPC 157 5mg 5 Vials Research FAQ Which testing documents are available for BPC 157 5mg 5 Vials
That series is available for digital download, too: Why Do Vegetarians Have Higher Stroke Risk?.
